Meeting
2021 ASCO Annual Meeting
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
Authors
Tim H. Brümmendorf
Universitätsklinikum RWTH Aachen, Aachen, Germany
Tim H. Brümmendorf , Jorge E. Cortes , Lambert Busque , Carlo Gambacorti-Passerini , Leif Stenke , Andrea Viqueira , Eric Leip , Simon Purcell , Michael W Deininger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT02130557
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7037)
DOI
10.1200/JCO.2021.39.15_suppl.7037
Abstract #
7037
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).
First Author: Tim H. Brummendorf
Poster
2021 ASCO Annual Meeting
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
First Author: Carlo Gambacorti-Passerini
Poster
2011 ASCO Annual Meeting
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
First Author: H. Kantarjian
Poster
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
First Author: Carlo Gambacorti-Passerini